The U.S. government allocated more than 11,000 courses of Gilead Sciences Inc.’s Covid-19 treatment remdesivir to the four states being hardest hit by the fast-spreading outbreak in the United States.

Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19. 

Gilead Sciences started an early-stage study of the company’s antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.

The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.

The European Commission gave conditional approval for the use of remdesivir in severe COVID-19 patients following an accelerated review process, making the antiviral the region’s first authorized therapy to treat the virus.

Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $2,340 per patient for a 5-day treatment.

New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.

Gilead Sciences Inc. expects supply of the potential COVID-19 drug remdesivir to exceed two million courses by year-end, more than double the company’s previous target of 1 million.

Drugmaker Gilead Sciences will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing the company’s experimental drug remdesivir.

The U.S. Food and Drug Administration issued a warning to healthcare providers against administering the malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.